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Medullary thyroid carcinoma (MTC) is a rare disease and accounts
for 3–10% of all thyroid carcinomas (Hundahl et al, 1998).
Because MTC can only be cured surgically and no effective radio-
or chemotherapy are available, mortality of MTC is higher than of
differentiated thyroid carcinoma and accounts for up to 13.4%
of all deaths related to thyroid malignancies (Marsh et al, 1995).
Serum level of basel as well as of pentagastrin-stimulated calci-
tonin is as established tumour marker in MTC, which is supple-
mented by estimation of serum levels of carcinoembryonic antigen
(CEA). Hereby, early detection of metastases and local disease
relapse remain to pose a major clinical problem in MTC.
Searching for local relapse of distant metastases is often very diff-
icult and includes laboratory tests as well as selective venous
catheterization, ultrasound, octreotide scan, computer tomography
and magnetic resonance imgaging. Therefore, molecular detection
of circulating tumour cells may represent a new approach in order
to improve early diagnosis of metastasized MTC.
In a recent study (Bojunga et al, 2000) we could show that detec-
tion of thyroglobulin mRNA in peripheral blood of patients with
differentiated thyroid carcinoma by RT-PCR correlated with the
diagnosis of metastasized thyroid carcinoma, although high assay
senitivities resulted in non-specific transcript-amplification. In this
study we now tested whether detection of circulating calcitonin and
carcinoembryonic mRNA in peripheral blood of patients with
medullary thyroid carcinoma may be a diagnostic tool for identi-
fying patients with local disease recurrence or metastasized MTC.
METHODS 
Cell culture 
TT cells, a medullary carcinoma cell line producing high levels of
calcitonin and carcinoembryonic antigen, was purchased from the
American Type Culture Collection. Cells were cultured in RPMI
1640 medium supplemented with 15% fetal calf serum, 10 mM
HEPES, 6 mM glutamine. The medium was changed every 3 days
and cells were harvested at confluence. 
Patients 
After approval by the human study committee 11 patients with
medullary thyroid carcinoma and 32 control subjects without
evidence or history of thyroid disease were studied. Diagnosis
of cancer was based on histological examination of the surgical
specimen. Diagnosis of healthy individuals was based on an
appropriate ultrasound examination and normal serum markers
(calcitonin, carcinoembryonic antigen, thyroid-stimulating
hormone (TSH), total thyroxin (T4) and triiodothyronine (T3)).
All patients with a diagnosis of medullary thyroid carcinoma
had been treated surgically and were followed in the Department
of Endocrinology at the Johann Wolfgang Goethe-University
Hospital and volunteered to participate in the study. 
Blood samples and RNA extraction 
The interval between surgery and collecting of blood samples
was >1 month in all patients with MTC. Blood samples were
prepared as described earlier (Bojunga et al, 2000). In brief,
approximately 9 ml venous blood was obtained from each
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patient in the morning prior to any diagnostic procedure in our
outpatient clinic at a routine appointment. Blood samples were
immediately mixed with EDTA to prevent coagulation and
cooled down to 4˚C. Nucleated cells were isolated using a
Percoll gradient (Pharmacia, Uppsala, Sweden) at a density of
1.09 g/ml within 2 h after withdrawal of blood. Serum for calci-
tonin, CEA and thyroid hormone measurements was obtained
using the supernatant after centrifugation. Total cellular RNA
was extracted using RNeasy blood kit (Qiagen, Hilden,
Germany) according to the suggestions of the manufacturer and
RNA was resuspended in 50 µ l RNase-free water. Optical trans-
mission of the final RNA-preparation was determined three
times at 260 nm using a Gene-Quant calculator (Pharmacia
Biotech, Freiburg, Germany) and the RNA concentration was
calculated. 
Oligonucleotide primers and probes 
Calcitonin primers were used as described elsewhere (Bracq et al,
1993). CEA primers were custom designed according to the
human CEA cDNA sequence reported by Barnett et al (Gene
Bank accession number M29540). All primers were synthesized
and purified by MWG-Biotech (Ebersberg, Germany). CT
primers bind exon 3 and 4 respectively, generate a 291 bp frag-
ment and span a genomic DNA sequence so that cDNA and
contaminating genomic DNA amplification products can be
distinguished by size. CEA primers bind exon 2 and 4 respec-
tively and generate a 328 bp fragment. To assess the intactness
of amplifiable RNA two intron-spanning glyceraldehyde-3-
phosphate-dehydrogenase (GAPDH) primers that generate 
a 300 bp fragment (Gene Bank accession number M33197) 
were used. The specificity of the primer sets for CT, CEA and
glyceraldehyde-3-phosphate-dehydrogenase, respectively, was
verified by basic local alignment search tool (BLAST) computer
search (Altschul et al, 1990). The sequences of these PCR
primers are listed in Table 1. 
Reverse transcriptase–polymerase chain reaction 
Approximately 1.5 µ g of total RNA was reverse transcribed in a
final volume of 20 µ l containing 4 µ l 5× buffer (250 mM Tris-
HCl pH 7.5, 375 mM KCl, 15 mM MgCl2, 50 mM DTT), 20
units recombinant RNase inhibitor (Promega, Madison, WI,
USA), 0.5 mM dNTP, 2.5 µ M oligo dT and 200 units RNAse H
minus M-MLV reverse transcriptase (Promega). The following
PCR was performed in a total volume of 50 µ l containing 3 µ l of
the RT-solution, 5 µ l 10× reaction buffer (200mM Tris-HCl pH
8.4, 500 mM KCl), 0.5 µ M forward and reverse primer, 0.2 µ M
of each dNTP, 2.5 units Taq-DNA polymerase and 1.5 mM MgCl2
(Life Technology, Paisley, Scotland) using a tube-controlled DNA
thermal cycler (AGS-Hybaid, Heidelberg, Germany). For
amplification of CEA cDNA, samples were subjected to 3 min
of denaturation at 94˚C followed by 30 cycles of 45 s at 94˚C,
30 s at 55˚C and 1 min 30 s at 72˚C, followed by additional 10
min at 72˚C. For amplification of CT cDNA, samples were
subjected to 3 min of denaturation at 94˚C followed by 10
cycles of 45 s at 94˚C, 30 sec at 65˚C decrescendo cycle-by-
cycle to 55˚C and 1 min at 72˚C, followed by 20 cycles of 45 s at
94˚C, 30 s at 55˚C and 1 min at 72˚C followed by additional 10 min
at 72˚C. In each experiment water was used as a negative control.
Analysis of amplified CT/CEA cDNA 
10 µ l PCR product was mixed with 2 µ l 6× loading dye (MBI
Fermentas, Vilnius, Lithuania) and run for 60 min on an 1.5%
agarose gel in TBE buffer (0.1 M Tris pH 8.4, 90 µ M boric acid,
1 mM EDTA). The gel was stained with ethidium bromide and
the bands corresponding to the amplified fragments were visu-
alized on UV-table. Sequencing of amplified CT/CEA fragments
was performed using a commercial sequencing service (SeqLab,
Göttingen, Germany). 
Calcitonin/carcinoembryonic antigen RT-PCR assay
sensitivity 
RT-PCR assay sensitivity was determined by mixing total RNA
isolated from whole blood of a negative control patient (negative
with CT and CEA RT-PCR) with total RNA isolated from TT cell
line in serial dilutions of 1:2, 1:5 and 1:10 steps, respectively. RT-
PCR was performed and analysed as described above. Assuming
that one TT cell contains approximately 10 pg total RNA, the
lower detection limit of the described RT-PCR assay was calcu-
lated as TT cells/ ml whole blood. 
Statistics 
Statistical comparisons were done using Sigma-Stat statistical
software (Jandel Scientific, Erkrath, Germany). Contingency
tables were used to assess the association between RT-PCR posi-
tivity rates and research subject category. Fisher exact test was
used to compare the distributions in contingency tables that had 5
or less expected observations in one or more cells. P < 0.05 was
considered significant. 
RESULTS 
Detection of CT and CEA transcripts by RT-PCR 
After optimization of conditions for reverse transcription and poly-
merase chain reaction we were able to detect calcitonin as well as
Table 1 Oligonucleotides and primers 
Oligonucleotide Sequence Size of amplicon Gene Bank accession 
Calcitonin primer (+) 5′ GGCAGCCTCCATGCAGCACC 3′ 291 J00109 
Calcitonin primer (–)5 ′ CCAGGTGCTCCAACCCC 3′
CEA primer (+) 5′ GACTCAGGACGCAACCTACC 3′ 328 M29540 
CEA primer (–)5 ′ ATTGCTGGAAAGTCCCATTG 3′
GAPDH primer (+) 5′ CGTCTTCACCACCATGGAGA 3′ 300 M33197 
GAPDH primer (–)5 ′ CGGCCATCACGCCACAGTTT 3′1548 J Bojunga et al 
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carcinoembryonic antigen transcripts as the expected 291/328 bp
amplicons in total RNA extracted from TT-cell culture by agarose
gel electrophoresis (Figure 1). PCR products were sequenced and
their identity was consistent with human calcitonin/carcinoembry-
onic antigen cDNA sequence (Gene bank accession numbers see
Table 1). PCR amplification using total RNA isolated from TT-cells
without prior reverse transcription was performed as described
above. PCR without RT was unsuccessful in amplifying the prod-
ucts predicted from the cDNA sequence. 
Sensitivity of RT-PCR assay 
RT-PCR assay sensitivity was determined using mixed aliquots of
total RNA isolated from TT-cells and lymphocytes of a negative
control patient. Assuming that one TT-cell contains 10 pg total
RNA, we could detect the equivalent of 200 TT-cells/ml blood
using calcitonin PCR and 50 TT-cells/ml blood using carcino-
embryonic antigen PCR by agarose gel electrophoresis (Figure 2). 
Evaluation of RT-PCR assay in patients and controls 
We evaluated 11 patients with medullary thyroid cancer, 7 of them
with known metastasis (local recurrence), and 32 control patients
without clinical signs or a history of thyroid disease. RT-PCR on
all blood samples was performed using primers for calcitonin and
carcinoembryonic antigen, respectively. Synthesis of cDNA was
achieved in all cases, as determined by successful amplification of
GAPDH cDNA in each sample. 
Using primers for calcitonin, we detected calcitonin mRNA in
peripheral blood of 0/11 patients with MTC and 0/32 controls.
Using primers for CEA, we detected CEA-mRNA in peripheral
blood of 8/11 (72.7%) patients with MTC and 11/32 (34.4%)
controls (P = 0.038; Fisher-exact-test; Table 2). 
Figure 3 exemplarily shows a patient with sporadic medullary
thyroid carcinoma and a nearly 10-year history of the disease. After
multiple surgical interventions, tumour mass increased rapidly and
the patient was no longer operable. Peripheral blood samples taken
from this patient over a period of 6 months were always tested
negative for calcitonin but positive for carcinoembryonic antigen
mRNA. Calcitonin serum level was > 16 500 pg/ml (normal value
< 20 pg/ml) and carcinoembryonic antigen serum level was
141 ng/ml (normal value < 4 ng/ml). 
Table 2 RT-PCR positivity rates for carcinoembryonic antigen mRNA in
patients with MTC and controls. Significant correlation between existence of
medullary thyroid carcinoma and a positive CEA RT-PCR result (P = 0.038;
Fisher-exact-test) 
RT-PCR positive cases 
No. of cases No. % 
Patients with MTC 11 8 72.7 
Controls 32 11 34.4 
A
B
Figure 1 Agarose gel electrophoresis of CT (A) and CEA (B) reverse-
transcriptase polymerase chain reaction products (291 bp and 328 bp,
respectively) derived from total RNA from TT-cell line 
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Figure 2 Calcitonin RT-PCR sensitivity assay. Total RNA isolated from TT cell line was mixed with total RNA from peripheral-blood mononuclear cells.
Sensitivity after 30 cycles of PCR amplification is shown. By ethidium bromide staining, calcitonin mRNA equivalent to 200 cells/ml blood was visualised
Figure 3 Patient with sporadic medullary thyroid carcinoma and a nearly
10-year history of the disease. After multiple surgical interventions, tumour
mass increased rapidly and the patient was no longer operable. Peripheral
blood samples taken from this patient over a period of 6 months were always
negative tested for calcitonin but positive for carcinoembryonic antigen
mRNA. Calcitonin serum level was >16 500 pg/ml (normal value <20 pg/ml)
and carcinoembryonic antigen serum level was 141 ng/ml (normal value 
<4 ng/ml) Circulating CT and CEA mRNA in MTC  1549
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DISCUSSION 
Diagnosis of local disease recurrence or metastasis in medullary
thyroid carcinoma (MTC) remains to pose a diagnostic challenge
in clinical practice. In this study, we evaluated whether detection
of circulating calcitonin and CEA mRNA may add additional
information to established studies for detection of recurrent
disease. Molecular detection of tissue specific gene expression in
peripheral blood is a new diagnostic approach and has been
described as a tumour marker in different solid tumours (Johnson
et al, 1995). In some malignant diseases – for example prostate
cancer – detection of circulating tumour cells could be shown to
precede the detection of secondary disease by serum markers
determined by immunoassays (Ghossein et al, 1995). One study
has been published, which has explored blood borne cytokeratin
20 mRNA as a potential tumour marker in thyroid cancer,
especially MTC (Weber et al, 2000). To date, calcitonin and
carcinoembryonic antigen mRNA have only been described as
diagnostic tools for preoperative diagnosis of MTC in leftover
cells from fine needle aspiration biopsy (Takano et al, 1999;
Bugalho et al, 2000).
Using RT-PCR, calcitonin mRNA could neither be detected in
peripheral blood of patients with MTC nor in controls in the
present study, although serum levels of calcitonin (CT) were
elevated in all patients with MTC and disease recurrence.
Furthermore, multiple peripheral blood samples could be analysed
for CT mRNA in a patient with known metastasis and massive
tumour mass in the neck (Figure 3). Despite the fact that CT serum
levels were highly increased in this patients, detection of circu-
lating CT mRNA in this patient failed over a period of 6 months.
Although RT-PCR is a highly sensitive method of detect tumour
and tissue-specific mRNA, for several reasons, detection of CT-
mRNA in peripheral blood may have failed. 
First, RT-PCR assay-sensitivity may be to low to detect circu-
lating CT-mRNA. We could determine assay-sensitivity to detect
200 CT-mRNA experssing cells/ml whole blood. This sensitivity
is in the range of other comparable studies (Ditkoff, et al 1996;
Weber et al, 2000). From a technical point of view assy-sensitivity
can be increased easily, but as we and others have described
earlier, higher assay- sensitivities resulted in completely unspe-
cific results (Tallini et al, 1998; Bojunga et al, 2000). Other inves-
tigators were able to detect cytokeratin 20 mRNA – suspected as a
tumour specific marker – in peripheral blood of three out of eight
patients with MTC and concluded that CK20 RT-PCR assay is able
to detect circulating tumour cells in peripheral blood of thyroid
carcinoma patients (Weber et al, 2000). However, the limitation of
this study is that tissue specificity of the transcripts was not evalu-
ated and as others have shown (Jung et al, 1999), the detection of
micrometastasis by cytokeratin 20 RT-PCR is limited due to stable
background transcription in granulocytes. In addition, blood
samples from only eight patients with MTC were studied. In view
of these results, further studies are necessary to determine whether
cytokeratin 20 may be a candidate for detection of circulating
tumour cells in MTC as well. 
Second, medullary thyroid carcinoma exhibits several biological
peculiarities. Before metastasis in a distant site can develop,
tumour cells must circulate in the peripheral blood or lymphatic
channels. MTC typically forms metastasis in the local lymph nodes
of the neck region and of the proximal mediastinum (Bergholm
et al, 1989). In patients with elevated basal calcitonin values during
family screening programs, local lymph node involvement could be
found in 50% of patients. Patients with clinically manifest tumours
suffered from local metastases in 71% of cases (Wells et al, 1978).
Local lymph node involvement is the strongest predictor for disease
survival in MTC: in the study of Woolner et al (Woolner et al, 1969)
the 10-year survival rate of patients without lymph node involve-
ment was not significantly different to a reference population
(85%), whereas survival was reduced to 42% in patients with
lymph node involvement. So the reason for the failure of detecting
CT-mRNA expressing cells in our patients with MTC may be that
tumour cells may only circulate in peripheral blood very late in the
natural history of the disease. Furthermore, occurrence of negative
peripheral blood samples in patients with metastatic disease has
been noted in other tumour models, and intermittent release of
tumour cells in the bloodstream may be one additional explanation
(Ghossein and Rosai, 1996). 
Using primers specific for CEA, we could detect CEA mRNA
significantly more often in patients with MTC (72,7%) than in
controls (34,4%; P < 0.05). However, specificity and sensitivity
are major concerns in RT-PCR systems for the detection of tumour
cells in peripheral blood. Circulating CEA mRNA has widely been
used in detection of metastasis in colo-rectal carcinoma and
conflicting data have been published concerning false positive
results for CEA mRNA in control patients: two groups using iden-
tical primer sequences did not find false positive cases in their
studies and therefore reached assay specificity of 100% (Gerhard
et al, 1994; Taniguchi et al, 2000), whereas other groups reported
false positive rates between 23% in bone marrow samples from
healthy controls (Jonas et al, 1996) and 26% in peripheral blood
samples from healthy controls (Zippelius et al, 1997). Using our
CEA RT-PCR assay with a sensitivity of 50 cells/ml blood, we
were able to detect circulating CEA mRNA in 34% of healthy
controls. The reason for this high percentage of RT-PCR positive
controls remains unclear. One reason may be that non-specific low
level expression of a variety of genes in different cell types, or ille-
gitimate transcription, also occur in peripheral-blood leukocytes.
Therefore, detection of CEA mRNA in peripheral blood might
reflect detection of non-specific or illegitimate transcription in cell
types of non-c-cell origin – e.g., lymphocytes or granulocytes – as
it has been described earlier (Chelly et al, 1989). Multiple periph-
eral blood samples could be analysed for CEA mRNA from the
patient mentioned above (Figure 3). CEA serum levels were also
markedly increased in this patients and he was tested positive for
circulating CEA mRNA several times over a period of 6 months. 
Together, our results demonstrate that calcitonin mRNA does
not seem to be a candidate for the detection of circulating tumour
cells in MTC. However, in contrast to circulating calcitonin
mRNA, our data suggest that the use of carcinoembryonic
mRNA may provide a significant improvement in diagnosis of
recurrent disease in MTC. Additional studies with quantitative
assay format, larger groups of patients with long-term clinical
follow up and establishment of cut-off values are necessary to
further define the clinical value and diagnostic sensitivity and
specificity of CEA mRNA RT-PCR assays in detecting disease
recurrence in MTC. 
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